Cell-culture models of the blood-brain barrier
Incretin therapies The first generation of weight-loss medications are incretin therapies that regulate insulin secretion, building on type 2 diabetes mellitus (T2DM) treatments utilising glucagon-like peptide-1 (GLP-1) receptor agonists
This is where GLP-1/GIP medications, such as Wegovy, Ozempic, Zepbound, and Mounjaro, offer a new approach
Swirl to dissolve, do not shake
In addition, GLP1-RAs demonstrate numerous cardiovascular protective effects in subjects with or without diabetes
23, Novo Nordisk released late-stage study results showing participants who took its next-generation obesity drug, CagriSema, didn't lose as much weight as those who took rival Eli Lilly's Zepbound